Business Description
Marker Therapeutics Inc
NAICS : 325414
SIC : 2834
ISIN : US57055L2060
Total Employee Number:
5Description
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.79 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 30 | |||||
3-Year EPS without NRI Growth Rate | 31.6 | |||||
3-Year FCF Growth Rate | 41 | |||||
3-Year Book Growth Rate | -24.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 217.33 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 34.21 | |||||
9-Day RSI | 44.32 | |||||
14-Day RSI | 47.79 | |||||
3-1 Month Momentum % | -13.33 | |||||
6-1 Month Momentum % | -26.24 | |||||
12-1 Month Momentum % | -13.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.79 | |||||
Quick Ratio | 4.79 | |||||
Cash Ratio | 4.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -25.7 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -73.66 | |||||
ROA % | -60.54 | |||||
ROIC % | -820.93 | |||||
3-Year ROIIC % | -33.46 | |||||
ROCE % | -78.44 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.75 | |||||
Price-to-Tangible-Book | 1.69 | |||||
EV-to-EBIT | -0.74 | |||||
EV-to-EBITDA | -0.74 | |||||
EV-to-Forward-EBITDA | -0.61 | |||||
EV-to-Forward-Revenue | 3.53 | |||||
EV-to-FCF | -1.16 | |||||
| Price-to-Net-Current-Asset-Value | 1.69 | |||||
| Price-to-Net-Cash | 2.08 | |||||
Earnings Yield (Greenblatt) % | -135.19 | |||||
FCF Yield % | -33.67 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Marker Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.525 | ||
| Beta | -0.1091 | ||
| 3-Year Sharpe Ratio | -0.11 | ||
| 3-Year Sortino Ratio | -0.16 | ||
| Volatility % | 63.62 | ||
| 14-Day RSI | 47.79 | ||
| 14-Day ATR (€) | 0.041124 | ||
| 20-Day SMA (€) | 1.108 | ||
| 12-1 Month Momentum % | -13.33 | ||
| 52-Week Range (€) | 0.575 - 1.72 | ||
| Shares Outstanding (Mil) | 16.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Marker Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Marker Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 120 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 29 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 1.07 (+0.00%) | ||
| General meeting for 2026 | 2026-05-01 10:00 | 1.09 (+0.00%) | ||
| Annual report for 2025 | 2026-03-18 | 1.08 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-18 | 1.08 (+0.00%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-25 08:00 | 1.19 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 0.67 (+0.00%) | ||
| Marker Therapeutics Fireside Chat – H.C. Wainwright Conference | 2025-09-10 12:30 | 0.60 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 0.95 (+0.00%) |
Show
Entries
Marker Therapeutics Inc Frequently Asked Questions
What is Marker Therapeutics Inc(FRA:GX1)'s stock price today?
The current price of FRA:GX1 is €1.10. The 52 week high of FRA:GX1 is €1.72 and 52 week low is €0.57.
When is next earnings date of Marker Therapeutics Inc(FRA:GX1)?
The next earnings date of Marker Therapeutics Inc(FRA:GX1) is 2026-08-14 Est..
Does Marker Therapeutics Inc(FRA:GX1) pay dividends? If so, how much?
Marker Therapeutics Inc(FRA:GX1) does not pay dividend.
Press Release
Articles on Marker Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers